In conclusion, we suggest that the AGR2-IRE1α-XBP1 cascade is an ER-related pathway that regulates HCC progression; hence, this signaling cascade might be a potential therapeutic target for curing sorafenib-resistant HCC in the future. Here, XBP1 is linked to hepatocellular carcinoma.